Tesamorelin 10mg
Janoshik
Batch TESA-CA-26F-10
Tesamorelin
GHRH Analogue Research Peptide
Tesamorelin is a synthetic peptide studied in laboratory settings for its role in stimulating growth hormone–releasing pathways and downstream endocrine signaling. Research often examines its interaction with GH-related mechanisms, metabolic regulation processes, and broader hormonal communication systems in controlled experimental models.
This product is intended strictly for laboratory research use within the United States. It is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable U.S. federal, state, and local regulations.
Tesamorelin is a synthetic peptide analogue of growth hormone–releasing hormone (GHRH). It is developed for controlled laboratory research involving hypothalamic-pituitary signaling systems.
In scientific literature, tesamorelin is studied in experimental models examining GHRH receptor interaction, endocrine pathway signaling cascades, and downstream growth hormone–associated regulatory mechanisms under in vitro and preclinical research conditions.
Third-party tested for purity, identity, quantity.
Tesamorelin is a stabilized synthetic analogue of GHRH designed to extend receptor interaction duration within experimental systems. Research has examined its interaction with GHRH receptors and associated endocrine signaling frameworks in controlled laboratory environments.
Preclinical and clinical research publications have explored its receptor-binding characteristics and downstream growth hormone–associated pathway activity under structured study conditions.
Tesamorelin was developed through research efforts aimed at modifying native GHRH sequences to enhance stability and receptor interaction time. Investigations into GHRH pathway modulation led to the synthesis of stabilized analogues for experimental evaluation.
Subsequent studies documented its receptor-binding profile and signaling characteristics within endocrine research frameworks.
Laboratory investigations into tesamorelin have focused on GHRH receptor activation models and downstream endocrine signaling pathways. Research frameworks evaluate receptor-mediated interaction, hypothalamic-pituitary axis dynamics, and growth hormone–associated regulatory systems under controlled in vitro and preclinical conditions.
1 of the 4 areas below are addressed directly by a paper cited on this page.
GHRH receptor activation models
No paper cited on this page reports on ghrh, receptor or activation. This heading marks where Tesamorelin is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Hypothalamic-pituitary signaling studies
No paper cited on this page reports on hypothalamic or pituitary. This heading marks where Tesamorelin is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Endocrine regulatory pathway research
No paper cited on this page reports on endocrine. This heading marks where Tesamorelin is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Stabilized peptide analogue evaluation
Addressed on this page by Falutz 2010. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Falutz, J. et al. (2010) — Effects of tesamorelin (TH9507), a growth hormone–releasing factor analogue, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.
The references section of this page cites 3 primary papers published between 2010 and 2019 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Tesamorelin, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
Tesamorelin is also referred to as tesa.
Approved prescription medicines containing the same active ingredient are sold under the brand name Egrifta. The material supplied here is not those products and is not interchangeable with them. Those are regulated pharmaceuticals manufactured to a licensed specification and dispensed under medical supervision. This is a research compound, and what is published for it is its measured purity and content per lot.
Tesamorelin is commonly described online in connection with muscle growth, fat loss and improved recovery. In the research literature the same compound is filed under GHRH receptor activation models, hypothalamic-pituitary signaling studies and endocrine regulatory pathway research.
Of the 3 papers cited on this page, published between 2010 and 2019, 3 report work in human participants — Falutz 2010, Falutz 2010 and Stanley 2019. Human data for a molecule is not the same as evidence for material supplied as a research compound: published trials use pharmaceutical-grade product under medical supervision at defined doses. What is established for the material sold here is its measured purity and content per lot.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for Tesamorelin is per lot, not per product. Across the strengths currently stocked: 10mg lot TESA-CA-26F-10 returned 98.763% purity, 11.68 mg measured, 116.8% of the labelled 10 mg; 20mg lot TESA-CA-26F-20 returned 99.375% purity, 22.6 mg measured, 113% of the labelled 20 mg, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
Purity is half the number. It states what fraction of the material in the vial is Tesamorelin; it says nothing about how much material is in the vial, and a short-filled vial can return a purity result that is entirely accurate. The figure that answers the second question is measured mass against expected content — for Tesamorelin, across the strengths stocked they run from 113% to 116.8% of label. Both numbers are published for every lot, whichever way they fall.
Each strength of Tesamorelin carries its own lot code and its own certificate — TESA-CA-26F-10, TESA-CA-26F-20 are separate tests, not one result applied across the range. The code printed on the vial you receive is the one to match, and matching it is what ties the material in hand to a test that was actually run on it.
Researchers who buy Tesamorelin in the United States through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
- Lyophilized storage
- −20 °C long-term; stable at room temperature in transit
- After reconstitution
- 2–8 °C
- Light
- Protect from UV and direct light
- Freeze-thaw
- Avoid repeated cycles
- Vehicle
- Bacteriostatic water in most published protocols
- Format
- Lyophilized powder
Tesamorelin is supplied as lyophilized powder. In the dry state the material is comparatively stable, which is why it ships at ambient temperature without a cold chain; once reconstituted it is a peptide in solution and the handling constraints tighten considerably. At 44 residues it is short enough to be produced by solid-phase synthesis, and the published sequence on this page is what an identity assay is checked against.
Repeated freeze-thaw cycling is the handling error most likely to degrade material of this class, because each cycle concentrates solutes at the ice boundary. Where a protocol calls for the same vial across multiple sessions, the published literature generally describes aliquoting after reconstitution rather than re-freezing the whole volume.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
- 1 × sealed glass vial in the strength selected (10mg / Single Vial, 20mg / Single Vial, 10mg / 5-Pack, 10mg / 10-Pack, 20mg / 5-Pack, 20mg / 10-Pack available), batch-labelled
- The batch-linked Certificate of Analysis for the exact lot shipped
- Discreet outer packaging with no product names on the exterior
- FedEx, tracked, typically 1–3 business days domestically
- Bacteriostatic water or any other reconstitution vehicle
- Syringes, needles or filters
- Dosing, administration or protocol guidance of any kind
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each vial contains 10mg of lyophilized tesamorelin. Independent third-party testing verifies purity, identity, and net content per batch.
The vial contains only the peptide preparation. Any laboratory materials required for experimental procedures must be sourced separately.
Duration depends entirely on research protocol, storage conditions, and laboratory application.
Effects of tesamorelin (TH9507), a growth hormone–releasing factor analogue, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.
PubMedEffects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 95(9):4291–4304.
PubMedEffects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV 6(12):e821–e830.
PubMedRelated
You May Also Like
Next-generation GLP receptor agonist studied for metabolic signaling and nutrient partitioning pathways
From$79.99
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
From$39.99
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
From$59.99
Long-acting amylin analog engineered for appetite signaling, metabolic control, and energy balance research
From$99.99